/2395.T

2395.T Stock - Shin Nippon Biomedical Laboratories, Ltd.

Q: What is the analyst price target for 2395.T?

Analyst price target information is not currently available for 2395.T.

Q: What is 2395.T's market cap?

Market capitalization information is not currently available for 2395.T.

Healthcare|Medical - Diagnostics & Research|JPX

$1794.00-2.39%

$44.00 (-2.39%) • Dec 23

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1973.40

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for 2395.T

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-0.43

52W High$2005.00

52W Low$1142.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	$32.41B	$26.45B	$25.09B	$17.75B	$15.11B
Gross Profit	$16.57B	$14.28B	$13.05B	$9.69B	$7.55B
Gross Margin	51.1%	54.0%	52.0%	54.6%	50.0%
Operating Income	$2.99B	$4.16B	$5.25B	$4.20B	$2.53B
Net Income	$4.92B	$5.53B	$6.06B	$7.13B	$3.66B
Net Margin	15.2%	20.9%	24.2%	40.2%	24.2%
EPS	$118.30	$132.86	$145.57	$171.21	$87.96

Company Overview

Shin Nippon Biomedical Laboratories, Ltd., a contract research organization, provides drug discovery and development services in Japan and internationally. It offers pre-clinical laboratory services, such as good laboratory practice inspections; general and specific toxicity studies; pathological examinations; PK/PD of biopharmaceuticals, immunotoxicity tests, and antibody production; reproductive and developmental toxicity studies; pharmacology and pharmacological efficacy studies; and imaging services. The company also engages in the establishment and validation of analytical methods, analysis of biological samples, and calculation of pharmacokinetic parameters; and provides absorption, distribution, metabolism, and excretion studies using radioisotope-labeled compounds. In addition, it provides site management organization services for clinical trials; clinical contract research organization services; and translational research services, including research and development of nasal delivery systems, nucleic acid adjuvants, and regenerative medicines. The company was founded in 1957 and is headquartered in Tokyo, Japan.

Visit Website

Earnings History & Surprises

2395.T

Beat Rate

73%

Last 11 quarters

Avg Surprise

+38.5%

EPS vs Estimate

Beats / Misses

8/3

Last 12 quarters

Latest EPS

$19.23

Q4 2025

EPS Surprise History

Q1 24

-51.5%

$19.90vs$41.02

Q2 24

+221.2%

$41.72vs$12.99

Q3 24

-88.2%

$2.94vs$24.97

Q4 24

+8.0%

$29.04vs$26.89

Q1 25

+106.6%

$45.03vs$21.80

Q2 25

+102.4%

$41.30vs$20.41

Q3 25

No data

Q4 25

No data

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q4 2025	Nov 7, 2025	—	$19.23	—	—
Q3 2025	Aug 8, 2025	—	$6.26	—	—
Q2 2025	May 8, 2025	$20.41	$41.30	+102.4%	✓ BEAT
Q1 2025	Feb 5, 2025	$21.80	$45.03	+106.6%	✓ BEAT
Q4 2024	Nov 6, 2024	$26.89	$29.04	+8.0%	✓ BEAT
Q3 2024	Aug 6, 2024	$24.97	$2.94	-88.2%	✗ MISS
Q2 2024	May 8, 2024	$12.99	$41.72	+221.2%	✓ BEAT
Q1 2024	Feb 2, 2024	$41.02	$19.90	-51.5%	✗ MISS
Q4 2023	Nov 7, 2023	$26.97	$38.26	+41.9%	✓ BEAT
Q3 2023	Aug 2, 2023	$20.29	$32.99	+62.6%	✓ BEAT
Q2 2023	May 8, 2023	$26.44	$41.03	+55.2%	✓ BEAT
Q1 2023	Jan 31, 2023	$24.61	$-1.63	-106.6%	✗ MISS
Q4 2022	Oct 31, 2022	$34.53	$59.46	+72.2%	✓ BEAT
Q3 2022	Jul 29, 2022	—	$46.70	—	—
Q2 2022	May 6, 2022	—	$45.15	—	—
Q1 2022	Feb 2, 2022	—	$41.90	—	—
Q4 2021	Nov 2, 2021	—	$40.29	—	—
Q3 2021	Aug 4, 2021	—	$43.87	—	—
Q2 2021	May 10, 2021	—	$52.49	—	—
Q1 2021	Feb 5, 2021	—	$8.11	—	—

Frequently Asked Questions about 2395.T

What is 2395.T's current stock price?

Shin Nippon Biomedical Laboratories, Ltd. (2395.T) is currently trading at $1794.00 per share. The stock has moved -2.39% today.

What is the analyst price target for 2395.T?

No analyst price targets are currently available for this stock.

What sector is Shin Nippon Biomedical Laboratories, Ltd. in?

Shin Nippon Biomedical Laboratories, Ltd. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the JPX exchange.

What is 2395.T's market cap?

Shin Nippon Biomedical Laboratories, Ltd. has a market capitalization of $74.69 billion, making it a large-cap company.

Does 2395.T pay dividends?

No, Shin Nippon Biomedical Laboratories, Ltd. does not currently pay a dividend to shareholders.